SHINEWAY PHARM Reports 18% Revenue Decline in Q1 2026

Stock News

05/07

SHINEWAY PHARM (02877) announced that the Group's unaudited management accounts for the three months ended March 31, 2026, show revenue reached RMB 624 million. This represents a decrease of 18.0% compared to the same quarter in 2025. The performance by product category was as follows: revenue from injectable products decreased by 35.9% to RMB 168 million; revenue from soft capsule products increased by 32.1% to RMB 107 million; revenue from granule products increased by 24.8% to RMB 146 million; revenue from traditional Chinese medicine formula granules products decreased by 32.8% to RMB 164 million; and revenue from other dosage forms decreased by 31.6% to RMB 39 million.

Analyzed by product type, in the first quarter of 2026, injectable products, soft capsule products, granule products, and traditional Chinese medicine formula granules products accounted for approximately 26.9%, 17.1%, 23.4%, and 26.3% of the Group's total revenue, respectively.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1173549406"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173549406\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173549406?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 17:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173549406","market":"hk","top_or_hot":-1,"title":"SHINEWAY PHARM Reports 18% Revenue Decline in Q1 2026","media":"Stock News","content":"<p>SHINEWAY PHARM (02877) announced that the Group's unaudited management accounts for the three months ended March 31, 2026, show revenue reached RMB 624 million. This represents a decrease of 18.0% compared to the same quarter in 2025. The performance by product category was as follows: revenue from injectable products decreased by 35.9% to RMB 168 million; revenue from soft capsule products increased by 32.1% to RMB 107 million; revenue from granule products increased by 24.8% to RMB 146 million; revenue from traditional Chinese medicine formula granules products decreased by 32.8% to RMB 164 million; and revenue from other dosage forms decreased by 31.6% to RMB 39 million.</p>\n<p>Analyzed by product type, in the first quarter of 2026, injectable products, soft capsule products, granule products, and traditional Chinese medicine formula granules products accounted for approximately 26.9%, 17.1%, 23.4%, and 26.3% of the Group's total revenue, respectively.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SHINEWAY PHARM Reports 18% Revenue Decline in Q1 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSHINEWAY PHARM Reports 18% Revenue Decline in Q1 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-07 17:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SHINEWAY PHARM (02877) announced that the Group's unaudited management accounts for the three months ended March 31, 2026, show revenue reached RMB 624 million. This represents a decrease of 18.0% compared to the same quarter in 2025. The performance by product category was as follows: revenue from injectable products decreased by 35.9% to RMB 168 million; revenue from soft capsule products increased by 32.1% to RMB 107 million; revenue from granule products increased by 24.8% to RMB 146 million; revenue from traditional Chinese medicine formula granules products decreased by 32.8% to RMB 164 million; and revenue from other dosage forms decreased by 31.6% to RMB 39 million.</p>\n<p>Analyzed by product type, in the first quarter of 2026, injectable products, soft capsule products, granule products, and traditional Chinese medicine formula granules products accounted for approximately 26.9%, 17.1%, 23.4%, and 26.3% of the Group's total revenue, respectively.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1173549406","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173549406","pubTimestamp":1778145618,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SHINEWAY PHARM (02877) announced that the Group's unaudited management accounts for the three months ended March 31, 2026, show revenue reached RMB 624 million. This represents a decrease of 18.0%...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1606":"中医药概念","02877":"神威药业"},"translate_title":"神威药业报告2026年第一季度收入下降18%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02877":1},"content_text":"SHINEWAY PHARM (02877) announced that the Group's unaudited management accounts for the three months ended March 31, 2026, show revenue reached RMB 624 million. This represents a decrease of 18.0% compared to the same quarter in 2025. The performance by product category was as follows: revenue from injectable products decreased by 35.9% to RMB 168 million; revenue from soft capsule products increased by 32.1% to RMB 107 million; revenue from granule products increased by 24.8% to RMB 146 million; revenue from traditional Chinese medicine formula granules products decreased by 32.8% to RMB 164 million; and revenue from other dosage forms decreased by 31.6% to RMB 39 million.\nAnalyzed by product type, in the first quarter of 2026, injectable products, soft capsule products, granule products, and traditional Chinese medicine formula granules products accounted for approximately 26.9%, 17.1%, 23.4%, and 26.3% of the Group's total revenue, respectively.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}